Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ARTL | DEFA14A | neutral | 5/10 | No summary provided | Jul 16, 2026 |
| ESPR | EFFECT | bearish | 5/10 | Esperion Therapeutics received SEC effectiveness on two shelf registration statements (File Nos. 333-201198 and 333-1971 | Jul 16, 2026 |
| ESPR | EFFECT | bearish | 5/10 | Esperion Therapeutics had four shelf registration statements (File Nos. 333-286631, 333-264303, 333-258396, 333-208701) | Jul 16, 2026 |
| PRQR | EFFECT | bearish | 5/10 | ProQR Therapeutics N.V. received SEC effectiveness on July 15, 2026 for its F-3 shelf registration (File No. 333-297272) | Jul 16, 2026 |
| INSM | 8-K | bullish | 6/10 | Insmed reported positive 12-month data from the ongoing open-label extension (OLE) study of TPIP (treprostinil palmitil | Jul 16, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a routine 6-K reporting the acquisition of ADSs by multiple PDMRs (directors and officers) through dividend re | Jul 16, 2026 |
| VRAX | 6-K | neutral | 4/10 | Virax Biolabs CEO James Foster provided a shareholder update summarizing fiscal 2026 audited results (cash $6.4M, total | Jul 16, 2026 |
| GLMD | 6-K | bullish | 6/10 | Galmed Pharmaceuticals announced a breakthrough development of a novel LNP cardiac-targeted formulation of its SCD1 inhi | Jul 16, 2026 |
| TOMZ | 8-K | neutral | 2/10 | TOMI Environmental Solutions announced a 1-for-3 reverse stock split of its common and Series A preferred stock, effecti | Jul 16, 2026 |
| CDT | 8-K | bearish | 5/10 | CDT Equity Inc. filed a 1-for-10 reverse stock split to maintain compliance with Nasdaq's minimum bid-price rule, effect | Jul 16, 2026 |
| ENGN | 8-K | neutral | 3/10 | enGene announced the resignation of Chairman Dr. Richard Glickman and the appointment of current board member Michael He | Jul 16, 2026 |
| GEVO | 8-K | neutral | 2/10 | Gevo announced the appointment of Todd Werpy, Ph.D., to its Board of Directors, effective August 20, 2026. Werpy, a form | Jul 16, 2026 |
| CRDF | 424B5 | bearish | 6/10 | Cardiff Oncology is raising approximately $9.1 million in net proceeds through a registered direct offering of 9,293,078 | Jul 16, 2026 |
| CRDF | 8-K | bearish | 6/10 | Cardiff Oncology priced a ~$10M registered direct offering of 8.57M shares + warrants at $1.05/unit (20% discount to las | Jul 16, 2026 |
| ARTL | PRESS-RELEASE | neutral | 4/10 | Artelo Biosciences announced new preclinical data for ART26.12, its FABP5 inhibitor, showing efficacy comparable to napr | Jul 16, 2026 |
| ABT | 8-K | bullish | 6/10 | Abbott reported Q2 2026 adjusted diluted EPS of $1.31, a 2.6% beat vs. consensus of $1.28, on reported sales of $12.593B | Jul 16, 2026 |
| HRMY | 8-K | bullish | 7/10 | Harmony Biosciences pre-announced record Q2 2026 WAKIX net product revenue of ~$261M (+30% YoY), reaffirmed full-year gu | Jul 16, 2026 |
| VCEL | PRESS-RELEASE | neutral | 1/10 | Vericel Corporation announced it will report its Q2 2026 results on July 30, 2026. | Jul 16, 2026 |
| PTCT | PRESS-RELEASE | neutral | 1/10 | PTC Therapeutics, Inc. announced it will report its Q2 2026 results on July 30, 2026. | Jul 16, 2026 |
| GANX | 8-K | neutral | 4/10 | Gain Therapeutics filed an 8-K announcing that its cash and cash equivalents are expected to fund operations into Q2 202 | Jul 16, 2026 |
| ABUS | 8-K | bullish | 7/10 | Arbutus received ~$178M from the Moderna settlement, filed three international patent lawsuits against Pfizer/BioNTech, | Jul 16, 2026 |
| GRFS | PRESS-RELEASE | neutral | 4/10 | Grifols announced first patient dosing in two Phase 3 trials (SIGMA and XPERT) seeking U.S. label expansion for its immu | Jul 16, 2026 |
| SNTI | S-3/A | bearish | 7/10 | Senti Biosciences filed Amendment No. 1 to its S-3 shelf registration statement to register 15,971,890 shares of common | Jul 16, 2026 |
| QUCY | PRESS-RELEASE | neutral | 4/10 | Quantum Cyber announced $2.09M in purchase orders at its subsidiary Quantum Drones Corporation, received as part of the | Jul 16, 2026 |
| BCTXL | PRESS-RELEASE | neutral | 3/10 | BriaCell announced that Sunnybrook's Odette Cancer Centre has joined its pivotal Phase 3 study of Bria-IMT plus an immun | Jul 16, 2026 |
| MDCX | PRESS-RELEASE | bullish | 5/10 | Medicus Pharma received FDA feedback and central IRB approval for its optimized Phase 2 study of Teverelix in men with a | Jul 16, 2026 |
| ATAI | DEFA14A, 8-K | bullish | 7/10 | Eli Lilly (LLY) has agreed to acquire AtaiBeckley (ATAI) for $6.75 per share in cash plus up to $2.50 per share in conti | Jul 16, 2026 |
| IMRN | 6-K | neutral | 4/10 | Immuron reported FY26 global sales of AUD$7.7M, up 6% year-over-year, driven by 10% growth in Australia and 7% in the US | Jul 16, 2026 |
| SIGY | 15-12G | bearish | 7/10 | Sigyn Therapeutics filed a Form 15-12G to terminate its SEC registration under Section 12(g) and suspend its duty to fil | Jul 16, 2026 |
| ISCO | 8-K | bullish | 6/10 | International Stem Cell Corporation (ISCO) signed a definitive agreement to sell its wholly-owned subsidiary, Lifeline C | Jul 16, 2026 |